Difference between revisions of "Vinblastine (Velban)"
Jump to navigation
Jump to search
m (updated links) |
|||
| Line 34: | Line 34: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/25/1965: Initial approval | *11/25/1965: Initial approval | ||
| − | *Uncertain date: Approved for generalized [[Hodgkin lymphoma|Hodgkin's disease]] (Stages III and IV, Ann Arbor modification of Rye staging system). | + | *Uncertain date: Approved for generalized [[Hodgkin lymphoma|Hodgkin's disease]] (Stages III and IV, Ann Arbor modification of Rye staging system). ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). | + | *Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for histiocytic lymphoma. | + | *Uncertain date: Approved for histiocytic lymphoma. ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for [[cutaneous T-cell lymphoma|mycosis fungoides]] (advanced stages). | + | *Uncertain date: Approved for [[cutaneous T-cell lymphoma|mycosis fungoides]] (advanced stages). ''(No supporting studies are cited)'' |
*Uncertain date: Approved for [[testicular cancer|advanced carcinoma of the testis]]. ''(Based on Loehrer et al. 1988)'' | *Uncertain date: Approved for [[testicular cancer|advanced carcinoma of the testis]]. ''(Based on Loehrer et al. 1988)'' | ||
| − | *Uncertain date: Approved for [[Kaposi sarcoma|Kaposi's sarcoma]]. | + | *Uncertain date: Approved for [[Kaposi sarcoma|Kaposi's sarcoma]]. ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). | + | *Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for [[Gestational trophoblastic neoplasia|choriocarcinoma resistant to other chemotherapeutic agents]]. | + | *Uncertain date: Approved for [[Gestational trophoblastic neoplasia|choriocarcinoma resistant to other chemotherapeutic agents]]. ''(No supporting studies are cited)'' |
| − | *Uncertain date: Approved for [[breast cancer|carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy]]. | + | *Uncertain date: Approved for [[breast cancer|carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy]]. ''(No supporting studies are cited)'' |
==Also known as== | ==Also known as== | ||
Revision as of 13:14, 4 September 2022
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Vinblastine (Velban) patient drug information (Chemocare)[3]
- Vinblastine (Velban) patient drug information (UpToDate)[4]
Diseases for which it is used
- Bladder cancer
- Lymphoma
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Non-small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Diseases for which it was used
- Breast cancer
- Head and neck cancer
- Melanoma
- Prostate cancer
- Renal cell carcinoma
- Small cell lung cancer
History of changes in FDA indication
- 11/25/1965: Initial approval
- Uncertain date: Approved for generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system). (No supporting studies are cited)
- Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). (No supporting studies are cited)
- Uncertain date: Approved for histiocytic lymphoma. (No supporting studies are cited)
- Uncertain date: Approved for mycosis fungoides (advanced stages). (No supporting studies are cited)
- Uncertain date: Approved for advanced carcinoma of the testis. (Based on Loehrer et al. 1988)
- Uncertain date: Approved for Kaposi's sarcoma. (No supporting studies are cited)
- Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). (No supporting studies are cited)
- Uncertain date: Approved for choriocarcinoma resistant to other chemotherapeutic agents. (No supporting studies are cited)
- Uncertain date: Approved for carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy. (No supporting studies are cited)
Also known as
- Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
- Brand names:
| Synonyms | ||||
|---|---|---|---|---|
| Alkaban-AQ | Blastovin | Cellblastin | Cytoblastine | Erbablas |
| Exal | Faulblastina | Lemblastine | Periblastine | Rabinefil |
| Velban | Velbastine | Velbe | Vinblasin | Vinblastin |
| Vinblastina | ||||
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Bladder cancer medications
- Desmoid tumor medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Kaposi sarcoma medications
- Langerhans cell histiocytosis medications
- Non-small cell lung cancer medications
- Testicular cancer medications
- Breast cancer medications (historic)
- Head and neck cancer medications (historic)
- Melanoma medications (historic)
- Prostate cancer medications (historic)
- Renal cell carcinoma medications (historic)
- Small cell lung cancer medications (historic)
- FDA approved in 1965
- WHO Essential Cancer Medicine